Find and Pitch Jounalists, Get Your Story Covered

Tags: Deal Evergreen Deals Entertainment Mobile Commerce 2022

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Palbociclib Regimen Yields 'Incredible' PFS Gain in Metastatic Breast Cancer - 19 days ago Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 4 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 6 months ago Most Cancer Drugs Granted Accelerated Approval Fail Confirmatory Trials - 9 months ago Chemotherapy/ICI Combos Falter as Second-Line Treatment for Gastric Cancer - 9 months ago Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - 10 months ago Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC - 11 months ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - about 1 year ago Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS - about 1 year ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - about 1 year ago Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer - about 1 year ago Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer - about 1 year ago
2	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer - 20 days ago FDA Grants Orphan Drug Designation for CAN-2409 to Treat Pancreatic Cancer - 9 months ago Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer - 9 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 9 months ago Osimertinib With Chemotherapy Could Aid Overall Survival for NSCLC - 9 months ago Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC - 9 months ago Phase 3 EVOKE-01 Study in Metastatic NSCLC Falls Short of Primary Endpoint - 11 months ago FDA Grants Priority Review for Pembrolizumab in Progressive Cervical Cancer - over 1 year ago
3	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	'Very Clear Signal' That Survival Improved With Addition of Durvalumab in SCLC - 6 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - about 1 year ago KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer - about 1 year ago New Data on CD40 Ligand Inhibitor for Relapsing MS - about 1 year ago
4	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 7 months ago
5	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 9 months ago Pembrolizumab, Chemoradiotherapy Meet Overall Survival Endpoint for Cervical Cancer - 10 months ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago
6	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advancements in HER2+ Breast Cancer Treatment: Insights From the HER2CLIMB-02 Trial - 11 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - about 1 year ago
7	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	GSK's Jemperli Plus Zejula Produces Significant Survival Improvement in Endometrial Cancer - about 1 year ago FDA Grants Orphan Drug Designation to Novel Treatment for Leptomeningeal Metastases in Breast Cancer - about 1 year ago
8	Wayne Kuznar MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer - about 1 year ago Maintenance Pembrolizumab-Olaparib Fails to Boost Survival in TNBC - about 1 year ago
9	Erin Hunter, Assistant Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	Golidocitinib Demonstrates Significant Survival Benefits For Patients with Peripheral T-cell Lymphoma - about 1 year ago FDA Approves First Therapy for Rare Invasive Tumor Type With High Risk of Recurrence - about 1 year ago Nivolumab Combination Regimen Improved Survival of Patients with Bladder Cancer By A Third Compared to Chemotherapy Alone - about 1 year ago Novel Oral Medication Reduces Risk of Death by 76% in Patients With ALK-Positive Lung Cancer - about 1 year ago
10	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials - about 1 year ago Completely Oral Regimen Effective, Feasible in APL - about 1 year ago Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - about 1 year ago

Journalists covering progression-free survival